139 related articles for article (PubMed ID: 23800670)
1. Hormone replacement therapy increases the risk of cranial meningioma.
Andersen L; Friis S; Hallas J; Ravn P; Schrøder HD; Gaist D
Eur J Cancer; 2013 Oct; 49(15):3303-10. PubMed ID: 23800670
[TBL] [Abstract][Full Text] [Related]
2. Hormone replacement therapy and risk of glioma: a nationwide nested case-control study.
Andersen L; Friis S; Hallas J; Ravn P; Gaist D
Cancer Epidemiol; 2013 Dec; 37(6):876-80. PubMed ID: 24138870
[TBL] [Abstract][Full Text] [Related]
3. Hormone replacement therapy and risk of meningioma in women: a meta-analysis.
Fan ZX; Shen J; Wu YY; Yu H; Zhu Y; Zhan RY
Cancer Causes Control; 2013 Aug; 24(8):1517-25. PubMed ID: 23702884
[TBL] [Abstract][Full Text] [Related]
4. Hormonal therapies and meningioma: is there a link?
Cea-Soriano L; Blenk T; Wallander MA; Rodríguez LA
Cancer Epidemiol; 2012 Apr; 36(2):198-205. PubMed ID: 21943794
[TBL] [Abstract][Full Text] [Related]
5. Hormone replacement therapy containing progestins and given continuously increases breast carcinoma risk in Sweden.
Olsson HL; Ingvar C; Bladström A
Cancer; 2003 Mar; 97(6):1387-92. PubMed ID: 12627501
[TBL] [Abstract][Full Text] [Related]
6. Hormone replacement therapy and the risk of melanoma in post-menopausal women.
Hicks BM; Kristensen KB; Pedersen SA; Hölmich LR; Pottegård A
Hum Reprod; 2019 Dec; 34(12):2418-2429. PubMed ID: 31803923
[TBL] [Abstract][Full Text] [Related]
7. Hormone replacement therapy and risk of non-fatal stroke.
Pedersen AT; Lidegaard O; Kreiner S; Ottesen B
Lancet; 1997 Nov; 350(9087):1277-83. PubMed ID: 9357407
[TBL] [Abstract][Full Text] [Related]
8. Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study.
Renoux C; Dell'aniello S; Garbe E; Suissa S
BMJ; 2010 Jun; 340():c2519. PubMed ID: 20525678
[TBL] [Abstract][Full Text] [Related]
9. Age and menopausal effects of hormonal birth control and hormone replacement therapy in relation to breast cancer risk.
Shantakumar S; Terry MB; Paykin A; Teitelbaum SL; Britton JA; Moorman PG; Kritchevsky SB; Neugut AI; Gammon MD
Am J Epidemiol; 2007 May; 165(10):1187-98. PubMed ID: 17337757
[TBL] [Abstract][Full Text] [Related]
10. A nationwide cohort study on the incidence of meningioma in women using postmenopausal hormone therapy in Finland.
Korhonen K; Auvinen A; Lyytinen H; Ylikorkala O; Pukkala E
Am J Epidemiol; 2012 Feb; 175(4):309-14. PubMed ID: 22287638
[TBL] [Abstract][Full Text] [Related]
11. Hormonal exposures and the risk of intracranial meningioma in women: a population-based case-control study.
Custer B; Longstreth WT; Phillips LE; Koepsell TD; Van Belle G
BMC Cancer; 2006 Jun; 6():152. PubMed ID: 16759391
[TBL] [Abstract][Full Text] [Related]
12. Is there an association between meningioma and hormone replacement therapy?
Blitshteyn S; Crook JE; Jaeckle KA
J Clin Oncol; 2008 Jan; 26(2):279-82. PubMed ID: 18182668
[TBL] [Abstract][Full Text] [Related]
13. Hormone replacement therapy and invasive and borderline epithelial ovarian cancer risk.
Mills PK; Riordan DG; Cress RD; Goldsmith DF
Cancer Detect Prev; 2005; 29(2):124-32. PubMed ID: 15829372
[TBL] [Abstract][Full Text] [Related]
14. Association of hormone replacement therapy with increased risk of meningioma in women: A hospital-based multicenter study with propensity score matching.
Shu X; Jiang Y; Wen T; Lu S; Yao L; Meng F
Asia Pac J Clin Oncol; 2019 Oct; 15(5):e147-e153. PubMed ID: 30761745
[TBL] [Abstract][Full Text] [Related]
15. Association of regimens of hormone replacement therapy to prognostic factors among women diagnosed with breast cancer aged 50-64 years.
Daling JR; Malone KE; Doody DR; Voigt LF; Bernstein L; Marchbanks PA; Coates RJ; Norman SA; Weiss LK; Ursin G; Burkman RT; Deapen D; Folger SG; McDonald JA; Simon MS; Strom BL; Spirtas R
Cancer Epidemiol Biomarkers Prev; 2003 Nov; 12(11 Pt 1):1175-81. PubMed ID: 14652277
[TBL] [Abstract][Full Text] [Related]
16. An analysis of the effect of selection bias on the association of hormone replacement therapy and breast cancer risk.
Csizmadi I; Friedenreich CM; Bryant HE; Courneya KS
Chronic Dis Can; 2005; 26(2-3):73-9. PubMed ID: 16251013
[TBL] [Abstract][Full Text] [Related]
17. Defining hormone replacement therapy in longitudinal studies: impact on measures of effect.
Csizmadi I; Collet JP; Benedetti A; Boivin JF; Hanley JA
Pharmacoepidemiol Drug Saf; 2004 Apr; 13(4):215-25. PubMed ID: 15255088
[TBL] [Abstract][Full Text] [Related]
18. Estrogen metabolism genotypes, use of long-term hormone replacement therapy and risk of postmenopausal breast cancer.
Cerne JZ; Novakovic S; Frkovic-Grazio S; Pohar-Perme M; Stegel V; Gersak K
Oncol Rep; 2011 Aug; 26(2):479-85. PubMed ID: 21567099
[TBL] [Abstract][Full Text] [Related]
19. A case-control study of hormone replacement therapy after primary surgical breast cancer treatment.
Ursic-Vrscaj M; Bebar S
Eur J Surg Oncol; 1999 Apr; 25(2):146-51. PubMed ID: 10218456
[TBL] [Abstract][Full Text] [Related]
20. Parity, infertility, oral contraceptives, and hormone replacement therapy and the risk of ovarian serous borderline tumors: A nationwide case-control study.
Rasmussen ELK; Hannibal CG; Dehlendorff C; Baandrup L; Junge J; Vang R; Kurman RJ; Kjaer SK
Gynecol Oncol; 2017 Mar; 144(3):571-576. PubMed ID: 28108026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
